AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23829026 — intervention group
Group type: COMPARATOR
Intervention: No monitoring of critical signals
Number of subjects: 0
Study 21729165 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-aminolevulinic acid (5-ALA) PDT at 25 mW/cm2
Number of subjects: 50
Study 21729165 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-aminolevulinic acid (5-ALA) PDT at 50 mW/cm2
Number of subjects: 50
Study 21729165 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-aminolevulinic acid (5-ALA) PDT at 75 mW/cm2
Number of subjects: 50
Study 19657610 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 300
Study 19657610 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 300
Study 16253380 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple actrapid and NPH insulin injections
Number of subjects: 0
Study 16253380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylurea and metformin+/‐acarbose
Number of subjects: 0
Study 16253380 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone and glimepiride
Number of subjects: 0
Study 16253380 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 14967744 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy (carboplatin 30 mg/m2 on days 1-5 of weeks 1, 3, and 5; radiotherapy 54.0 Gy to all risk volumes plus 10.0 Gy to high-risk volumes; 5 daily fractions of 1.8 Gy each per week)
Number of subjects: 40
Study 14967744 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemoradiotherapy
Number of subjects: 40
Study 11051743 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (nitrosorbid, cardiket) 80 mg/day
Number of subjects: 19
Study 11051743 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide 5‐mononitrate (mono mac) 51.5 mg/day
Number of subjects: 19
Study 9610959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen measurement in fresh plasma samples
Number of subjects: 0
Study 9610959 — intervention group
Group type: COMPARATOR
Intervention: Fibrinogen measurement in frozen plasma samples stored at -70 degrees C
Number of subjects: 0
Study 8223839 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release formulation containing metoprolol 100 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 0
Study 8223839 — intervention group
Group type: COMPARATOR
Intervention: Conventional combination tablet
Number of subjects: 0
Study 3532593 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine b.i.d. (49 patients)
Number of subjects: 96
Study 3532593 — intervention group
Group type: COMPARATOR
Intervention: 300 mg ranitidine nocte (47 patients)
Number of subjects: 96
Study 28890275 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision-training tool
Number of subjects: 151
Study 28890275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 151
Study 26524709 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetectable hsTnT (<LoD)
Number of subjects: 882
Study 26524709 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable hsTnT (≥LoD but ≤99th percentile)
Number of subjects: 882
Study 26524709 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated hsTnT (≥14 ng/L)
Number of subjects: 882
Study 24210368 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% viscous lidocaine
Number of subjects: 100
Study 24210368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23009738 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention for 3 months
Number of subjects: 160
Study 23009738 — intervention group
Group type: COMPARATOR
Intervention: Individual intervention for 3 months
Number of subjects: 160
Study 23009738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both group and individual interventions
Number of subjects: 160
Study 20799124 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 102
Study 20799124 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizer
Number of subjects: 102
Study 20799124 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridation
Number of subjects: 102
Study 20799124 — intervention group
Group type: COMPARATOR
Intervention: Control (other methods)
Number of subjects: 102
Study 18971406 — intervention group
Group type: EXPERIMENTAL
Intervention: CCDE program
Number of subjects: 228
Study 18971406 — intervention group
Group type: COMPARATOR
Intervention: Agency-directed care
Number of subjects: 228
Study 16583831 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/day plus MPA 2.5 mg/day (n = 7)
Number of subjects: 20
Study 16583831 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (n = 13)
Number of subjects: 20
Study 12503234 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated nutrition program
Number of subjects: 119
Study 12503234 — intervention group
Group type: COMPARATOR
Intervention: Comparison communes (control)
Number of subjects: 119
Study 10195603 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-min portion-size estimation training session
Number of subjects: 110
Study 10195603 — intervention group
Group type: COMPARATOR
Intervention: Control group (34 subjects not trained)
Number of subjects: 110
Study 7552059 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical titration of electrical stimulus for ECT
Number of subjects: 0
Study 7552059 — intervention group
Group type: COMPARATOR
Intervention: Dose predictive methods from two different ECT equipment instruction manuals
Number of subjects: 0
Study 2316883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (3 mg/min)
Number of subjects: 30
Study 2316883 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 30
Study 6444861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotion with hydrocortisone acetate ('Actinac')
Number of subjects: 44
Study 6444861 — intervention group
Group type: COMPARATOR
Intervention: Lotion without hydrocortisone acetate
Number of subjects: 44
Study 30773191 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 3 to 9 ml of iodined PolyEthylene Glycol (PEG) hydrogel
Number of subjects: 42
Study 30773191 — intervention group
Group type: COMPARATOR
Intervention: Standard clips only (control group)
Number of subjects: 42
Study 31322589 — intervention group
Group type: EXPERIMENTAL
Intervention: Elgydium Protection caries toothpaste used for brushing teeth twice a day for 6 months
Number of subjects: 29
Study 31322589 — intervention group
Group type: COMPARATOR
Intervention: Toothpastes with fluoride of the first generation (control group)
Number of subjects: 29
Study 28683939 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring balloon pre-dilation before drug-coated balloon (DCB) therapy
Number of subjects: 252
Study 28683939 — intervention group
Group type: COMPARATOR
Intervention: Standard DCB therapy
Number of subjects: 252
Study 25125442 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Sports™ for arm rehabilitation
Number of subjects: 18
Study 23932219 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistrain preparation of lactobacilli and bifidobacteria (6 × 10^10 organisms, one per day for 21 days)
Number of subjects: 1493
Study 23932219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1493
Study 23932219 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistrain preparation of lactobacilli and bifidobacteria
Number of subjects: 1493
Study 23932219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1493
Study 22025742 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging (SMS) for health education
Number of subjects: 143
Study 22025742 — intervention group
Group type: COMPARATOR
Intervention: Pamphlets for health education
Number of subjects: 143
Study 18452743 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving training
Number of subjects: 67
Study 18452743 — intervention group
Group type: COMPARATOR
Intervention: Education-only control
Number of subjects: 67
Study 16228108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular tenoxicam 20 mg once weekly for 1-3 weeks
Number of subjects: 69
Study 16228108 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenoxicam 20 mg/day for 3 weeks
Number of subjects: 69
Study 16228108 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 69
Study 14626186 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI)
Number of subjects: 98
Study 14626186 — intervention group
Group type: COMPARATOR
Intervention: Control (surgical operation alone)
Number of subjects: 98
Study 10658688 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Intervention (SMI)
Number of subjects: 562
Study 10658688 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (SMI Control)
Number of subjects: 562
Study 9305716 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-based quadruple induction therapy using an antilymphocyte globulin preparation (ATG)
Number of subjects: 458
Study 9305716 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-based dual or triple immunosuppression
Number of subjects: 458
Study 9305716 — intervention group
Group type: COMPARATOR
Intervention: CsA-based triple therapy
Number of subjects: 458
Study 9305716 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-based quadruple induction therapy using an interleukin-2 receptor antibody (BT563)
Number of subjects: 458
Study 8382131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinorphan (100 mg)
Number of subjects: 12
Study 8382131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3532209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical Prostaglandin E2 (0.5 mg in 2.5 ml triacetin-gel)
Number of subjects: 100
Study 3532209 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion alone
Number of subjects: 100
Study 29927822 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric technique during septorhinoplasty
Number of subjects: 30
Study 29927822 — intervention group
Group type: EXPERIMENTAL
Intervention: Distortion product otoacoustic emission results postoperatively
Number of subjects: 30
Study 29927822 — intervention group
Group type: COMPARATOR
Intervention: Control group (nasal surgery without piezoelectric technique)
Number of subjects: 30
Study 27671868 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-low imaging protocol (80-100 kV, 200 mAs, iohexol 300 mg iodine/ml, 1-1.5 ml/kg)
Number of subjects: 72
Study 27671868 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT protocol (120 kV, 200-300 mAs, iopamidol 370 mg iodine/ml, 1-1.5 ml/kg)
Number of subjects: 72
Study 25359278 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care
Number of subjects: 266
Study 25359278 — intervention group
Group type: COMPARATOR
Intervention: Standardized care
Number of subjects: 266
Study 23186297 — intervention group
Group type: EXPERIMENTAL
Intervention: Very mild injury (VMI) vignette
Number of subjects: 551
Study 23186297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild injury (MI) vignette
Number of subjects: 551
Study 23186297 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe injury (MSI) vignette
Number of subjects: 551
Study 21081261 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined condition (access to an integrated eHealth system for breast cancer (CHESS) and phone conversations with a Human Cancer Information Mentor)
Number of subjects: 0
Study 21081261 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-intervention groups (either access to CHESS or phone conversations with a Human Cancer Information Mentor)
Number of subjects: 0
Study 21081261 — intervention group
Group type: COMPARATOR
Intervention: Internet-only group
Number of subjects: 0
Study 18180639 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) plus Ropivacain (ROP) once a week
Number of subjects: 36
Study 18180639 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (GBP) alone
Number of subjects: 36
Study 15805957 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh tourniquet (Group A)
Number of subjects: 54
Study 15805957 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet (Group B)
Number of subjects: 54
Study 12713213 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including mailings, flyers, radio announcements, and group presentations.
Number of subjects: 210
Study 12713213 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' reasons for participating: interest in health (56%), interest in diet/health (51%), believing the program would be fun for their child (46%).
Number of subjects: 210
Study 12713213 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls' reasons for participating: program sounded like fun (70%).
Number of subjects: 210
Study 10571703 — intervention group
Group type: EXPERIMENTAL
Intervention: Information expressed as number needed to treat (NNT)
Number of subjects: 215
Study 10571703 — intervention group
Group type: EXPERIMENTAL
Intervention: Information expressed in relative terms
Number of subjects: 215
Study 10571703 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information provided)
Number of subjects: 215
Study 8703882 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon green laser treatment (n = 79)
Number of subjects: 78
Study 8703882 — intervention group
Group type: COMPARATOR
Intervention: Krypton red laser treatment (n = 72)
Number of subjects: 78
Study 2537795 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (10 mg i.v. bolus followed by 10 mg/hr constant infusion)
Number of subjects: 6
Study 2537795 — intervention group
Group type: COMPARATOR
Intervention: Human ANF (99-126) infusion
Number of subjects: 6
Study 776313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study 776313 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 0
Study 30526742 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 5345
Study 30526742 — intervention group
Group type: COMPARATOR
Intervention: Control vaccination
Number of subjects: 5345
Study 28241830 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated clothing (ITC)
Number of subjects: 234
Study 28241830 — intervention group
Group type: COMPARATOR
Intervention: Untreated clothing (NTC)
Number of subjects: 234
Study 25347418 — intervention group
Group type: EXPERIMENTAL
Intervention: SC + pharmaceutical medication management
Number of subjects: 30
Study 25347418 — intervention group
Group type: EXPERIMENTAL
Intervention: SC + psychological counselling
Number of subjects: 30
Study 25347418 — intervention group
Group type: COMPARATOR
Intervention: SC (standard care)
Number of subjects: 30
Study 22923258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.1 μg/kg
Number of subjects: 240
Study 22923258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 μg/kg
Number of subjects: 240
Study 22923258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 240
Study 22923258 — intervention group
Group type: COMPARATOR
Intervention: Control (Dexmedetomidine 0 μg/kg)
Number of subjects: 240
Study 22923258 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240
Study 20940335 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine (24 mg b.i.d.)
Number of subjects: 16
Study 20940335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19959115 — intervention group
Group type: EXPERIMENTAL
Intervention: RF ablation
Number of subjects: 191
Study 19959115 — intervention group
Group type: COMPARATOR
Intervention: Cryoablation
Number of subjects: 191
Study 22353021 — intervention group
Group type: EXPERIMENTAL
Intervention: Wechsler Adult Intelligence Scale‐Fourth Edition (WAIS‐IV) administered at baseline and again either 3 or 6 months later
Number of subjects: 54
Study 16021858 — intervention group
Group type: EXPERIMENTAL
Intervention: u-hCG (10,000 IU)
Number of subjects: 100
Study 16021858 — intervention group
Group type: COMPARATOR
Intervention: r-hCG (250 microg)
Number of subjects: 100
Study 12426913 — intervention group
Group type: EXPERIMENTAL
Intervention: Suctioned only
Number of subjects: 18
Study 12426913 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioned and suctioned
Number of subjects: 18
Study 12426913 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioned, manually hyperinflated and suctioned
Number of subjects: 18
Study 12426913 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 9638029 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g.kg‐1 load
Number of subjects: 30
Study 9638029 — intervention group
Group type: EXPERIMENTAL
Intervention: 95 g.kg‐1 load
Number of subjects: 30
Study 8032079 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (60 mg/die)
Number of subjects: 22
Study 8032079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2574550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (20 mg QD for two days)
Number of subjects: 22
Study 2574550 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg BID for 1 week)
Number of subjects: 22
Study 2574550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 55891 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated index group (patients with hidden psychiatric disorders)
Number of subjects: 1093
Study 55891 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (patients with hidden psychiatric disorders)
Number of subjects: 1093
Study 55891 — intervention group
Group type: EXPERIMENTAL
Intervention: Detected group of patients (those whose disorder was recognized)
Number of subjects: 1093
Study 55891 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild disorders
Number of subjects: 1093
Study 29478378 — intervention group
Group type: COMPARATOR
Intervention: Plyometric conditioning
Number of subjects: 47
Study 29478378 — intervention group
Group type: COMPARATOR
Intervention: Skill-based conditioning
Number of subjects: 47
Study 29478378 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 27895845 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent conjugate pneumococcal vaccine
Number of subjects: 496
Study 27895845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study 23407260 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilting sutures and suction drains (QS+DN group)
Number of subjects: 48
Study 23407260 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilting sutures alone (QS group)
Number of subjects: 48
Study 23407260 — intervention group
Group type: COMPARATOR
Intervention: Suction drains alone (DN group)
Number of subjects: 48
Study 22221277 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention that paired behavioral treatment with naltrexone
Number of subjects: 40
Study 22221277 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 40
Study 20122373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone plus mood stabilizer
Number of subjects: 240
Study 20122373 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus mood stabilizer
Number of subjects: 240
Study 18499110 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (4 mg prolonged release)
Number of subjects: 16
Study 18499110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16013623 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient ACL reconstruction
Number of subjects: 50
Study 16013623 — intervention group
Group type: COMPARATOR
Intervention: Inpatient ACL reconstruction
Number of subjects: 50
Study 16013623 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 12435211 — intervention group
Group type: EXPERIMENTAL
Intervention: Learned Irrelevance (LIRR) pre-exposure trials
Number of subjects: 0
Study 12435211 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent Inhibition (LI) pre-exposure trials
Number of subjects: 0
Study 12435211 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the number of CS pre-exposures in rabbits
Number of subjects: 0
Study 12435211 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent Inhibition (LI) in humans
Number of subjects: 0
Study 10526725 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm needles
Number of subjects: 50
Study 10526725 — intervention group
Group type: COMPARATOR
Intervention: 12.7-mm needles
Number of subjects: 50
Study 7747149 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 0
Study 7747149 — intervention group
Group type: COMPARATOR
Intervention: Omnivores
Number of subjects: 0
Study 2188495 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program and questionnaire (group I, 25 patients)
Number of subjects: 47
Study 2188495 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire only (group II, 22 patients)
Number of subjects: 47
Study 6108319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketazolam (once-a-day)
Number of subjects: 101
Study 6108319 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (three times a day)
Number of subjects: 101
Study 6108319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once or three times a day)
Number of subjects: 101
Study 31276189 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg every 2 weeks
Number of subjects: 687
Study 31276189 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 687
Study 31276189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study 28774898 — intervention group
Group type: EXPERIMENTAL
Intervention: trabectedin 1.5 mg/m2 as a 24-hour continuous intravenous infusion once every 3 weeks
Number of subjects: 518
Study 28774898 — intervention group
Group type: COMPARATOR
Intervention: dacarbazine 1,000 mg/m2 i.v. once every 3 weeks
Number of subjects: 518
Study 25774657 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 819
Study 23996244 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated bioactive stents (BAS)
Number of subjects: 28
Study 23996244 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 28